Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Hemab Therapeutics Holdings, Inc.

NASDAQ: COAG · Life Sciences · 3 alerts · CIK 2114044

Share price
$39.06Close, Nov 16
Market cap
$1.83B
Shares outstanding
46.73MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Hemab Therapeutics Holdings, Inc. filings on SEC EDGAR ↗

4:01 PM ET 10-Q
Financial Results

Hemab Therapeutics Holdings Q3 2026 Results: Net Loss of $27.3M, Loss Widens

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for bleeding disorders, including its lead candidate sutacimig currently in Phase 3 trials. The company remains pre-revenue, incurring significant operating losses as it advances its clinical pipeline, and anticipates the need for substantial additional funding to support its research and development programs.

Key figure
Net loss $27.3M
7:08 AM ET 8-K
Financial Results

Hemab Therapeutics Holdings Financial Results

Hemab Therapeutics reported financial results for the third quarter of 2026 and provided a corporate update on its clinical pipeline. The company transitioned to a late-stage biotech by initiating the SOLARA Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia and dosing the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding.

Term
Q3 2026

“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.”

Benny Sørensen, MD, PhD, CEO of Hemab

“As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year.”

Benny Sørensen, MD, PhD, CEO of Hemab

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.